BCTX BriaCell Therapeutics Corp.

Nasdaq briacell.com


$ 13.79 $ 0.65 (4.95 %)    

Friday, 24-Oct-2025 15:59:50 EDT
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 13.79
$ 13.18
$ 11.90 x 100
$ 14.68 x 10
$ 12.66 - $ 13.90
$ 6.00 - $ 190.50
82,430
na
25.98M
$ 0.37
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-16-2025 07-31-2025 10-K
2 06-16-2025 04-30-2025 10-Q
3 03-12-2025 01-31-2025 10-Q
4 12-16-2024 10-31-2024 10-Q
5 10-28-2024 07-31-2024 10-K
6 06-14-2024 04-30-2024 10-Q
7 03-18-2024 01-31-2024 10-Q
8 12-14-2023 10-31-2023 10-Q
9 10-25-2023 07-31-2023 10-K
10 06-14-2023 04-30-2023 10-Q
11 03-16-2023 01-31-2023 10-Q
12 12-14-2022 10-31-2022 10-Q
13 10-28-2022 07-31-2022 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 the-independent-data-safety-monitoring-board-has-issued-its-fourth-consecutive-positive-recommendation-following-review-of-safety-data-from-briacell-therapeutics-phase-3-study-of-bria-imt-plus-an-immune-checkpoint-inhibitor-for-metastatic-breast-cancer

Following its review, the DSMB raised no safety concerns and recommended that the study continue without modifications. DSMB me...

Core News & Articles

79 clinical sites across 23 US states are currently enrolling patients in BriaCell's pivotal Phase 3 study in metastatic br...

 briacell-therapeutics-collaborates-with-msk-cancer-centers-therapeutics-accelerator-cohort-program-to-accelerate-clinical-development-of-bria-ots-for-multiple-cancer-indications

Collaboration with MSK's Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of t...

Core News & Articles

Biomarkers identified in BriaCell's Phase 2 study are showing similar and encouraging trends in the ongoing pivotal Phase 3...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-s...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-s...

 hc-wainwright--co-maintains-buy-on-briacell-therapeutics-raises-price-target-to-40

HC Wainwright & Co. analyst Emily Bodnar maintains BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and raises the price t...

 briacell-publishes-breakthrough-cancer-immunotherapy-research-in-jci-insight-journal

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-s...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-s...

 briacell-joins-msks-2025-therapeutics-accelerator-to-fast-track-cancer-immunotherapy

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-s...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))), (TSX:BCT) ("BriaCell"), a clinical-stage biotechnology compa...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-s...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION